Effect of dopaminergic neurotoxin MPTP/MPP+ on coenzyme Q content

Life Sciences

Volumn 83, Issue 3-4, 2008, Pages 92-95

  Dhanasekaran, Muralikrishnan ^a   Karuppagounder, Senthilkumar S ^a   Uthayathas, Subramaniam ^a   Wold, Loren E ^b   Parameshwaran, Kodeeswaran ^a   Jayachandra Babu, R ^a   Suppiramaniam, Vishnu ^a   Brown Borg, Holly ^c  

^a AUBURN UNIVERSITY   (United States)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Coenzyme Q; MPTP; Oxidative stress; Parkinson's disease

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; NEUROTOXIN; UBIDECARENONE; UBIQUINONE; UBIQUINONE 9;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; CEREBELLUM; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME LOCALIZATION; GLIOMA CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYBRID CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROBLASTOMA CELL; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PONS; RAT; TISSUE DISTRIBUTION; ULTRAVIOLET SPECTROSCOPY;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; CELL LINE, TUMOR; CEREBELLUM; CEREBRAL CORTEX; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE AGENTS; HUMANS; MICE; MICE, INBRED C57BL; MPTP POISONING; PONS; UBIQUINONE;

ANIMALIA; MUS;

EID: 46749128091     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2008.04.016     Document Type: Article

References (42)

1. Albano C.B., Muralikrishnan D., and Ebadi M. Distribution of coenzyme Q homologues in brain. Neurochemical Research 27 5 (2002) 359-368
2. Beal M.F. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. Journal of Bioenergetics and Biomembrane 36 4 (2004) 381-386
3. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., and Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nature Neuroscience 3 12 (2000) 1301-1306
4. Beyer R.E. The participation of coenzyme Q in free radical production and antioxidation. Free Radical Biology and Medicine 8 6 (1990) 545-565
5. 10. Journal of the American College of Nutrition 20 6 (2001) 591-598
6. Dabbeni-Sala F., Di Santo S., Franceschini D., Skaper S.D., and Giusti P. Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity. FASEB Journal 15 1 (2001) 164-170
7. Dhanasekaran M., and Ren J. The emerging role of coenzyme Q-10 in aging, neurodegeneration, cardiovascular disease, cancer and diabetes mellitus. Current Neurovascular Research 2 5 (2005) 447-459
8. Dhanasekaran M., Uthayathas S., Karuppagounder S.S., Parameshwaran K., Suppiramaniam V., Ebadi M., and Brown-Borg H.M. Ebselen effects on MPTP-induced neurotoxicity. Brain Research 1118 1 (2006) 251-254
9. Ebadi M., Muralikrishnan D., Pellett L., Drees K., and Murphy T. Ubiquinone (coenzyme Q10) and complex-I in mitochondrial oxidative disorder of Parkinson's disease. Proceedings of the Western Pharmacology Society 43 (2000) 55-63
10. Ebadi M., Govitrapong P., Sharma S., Muralikrishnan D., Shavali S., Pellett L., Schaffer R., Albano C., and Eken J. Ubiquinone and mitochondria in oxidative stress of Parkinson's disease. Biological Signals and Receptors 10 3-4 (2001) 224-253
11. Gotz M.E., Gerstner A., Harth R., Dirr A., Janetzky B., Kuhn W., Riederer P., and Gerlach M. Altered redox state of platelet coenzyme Q10 in Parkinson's disease. Journal of Neural Transmission 107 1 (2000) 41-48
12. Horvath T.L., Diano S., Leranth C., Garcia-Segura L.M., Cowley M.A., Shanabrough M., Elsworth J.D., Sotonyi P., Roth H.R., Dietrich E.H., Matthews R.T., Barnstable Jr. C.J., and Edmond D.E. Coenzyme Q induces nigral mitochondrial uncoupling and prevents dopamine cell loss in a primate model of Parkinson's disease. Endocrinology 144 7 (2003) 2757-2760
13. Isobe C., Murata T., Sato C., and Terayama Y. Increase of oxidized/total coenzyme Q-10 ratio in cerebrospinal fluid in patients with Parkinson's disease. Journal of Clinical Neuroscience 14 4 (2007) 340-343
14. Kagen T., Davis C., Lin L., and Zakeri Z. Coenzyme Q10 can in some circumstances block apoptosis, and this effect is mediated through mitochondria. Annal of the New York Academy of the Science 887 (1999) 31-47
15. Kawamukai M. Biosynthesis, bioproduction and novel roles of ubiquinone. Journal of Bioscience and Bioengineering 94 6 (2002) 511-517
16. 10 in human plasma as a possible marker of oxidative stress. Journal of Lipid Research 37 1 (1996) 67-75
17. Lenaz G., Bovina C., Formiggini G., and Castelli G.P. Mitochondria, oxidative stress, and antioxidant defenses. Acta Biochimca Polonica 46 1 (1999) 1-21
18. Lonnrot K., Metsa-Ketela T., and Alho H. The role of coenzyme Q-10 in aging: a follow-up study on life-long oral supplementation Q-10 in rats. Gerontology 41 Suppl 2 (1995) 109-120
19. Manyam B.V., Dhanasekaran M., and Hare T. Neuroprotective effects of the antiparkinson drug Mucuna pruriens. Phytotherapy Research. 18 9 (2004) 706-712
20. Matthews R.T., Yang L., Browne S., Baik M., and Beal M.F. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proceeding of the National Academy of Sciences of the United States of America 95 15 (1998) 8892-8897
21. Maulik N., Yoshida T., Engelman R.M., Bagchi D., Otani H., and Das D.K. Dietary coenzyme Q (10) supplement renders swine hearts resistant to ischemia-reperfusion injury. American Journal of Physiology-Heart Circulatory Physiology 278 4 (2000) 1084-1090
22. Mochizuki H., Hayakawa H., Migita M., Shibata M., Tanaka R., Suzuki A., Shimo-Nakanishi Y., Urabe T., Yamada M., Tamayose K., Shimada T., Miura M., and Mizuno Y. An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America 98 19 (2001) 10918-10923
23. Mohanakumar K.P., Muralikrishnan D., and Thomas B. Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. Brain Research 864 2 (2000) 281-290
24. Muralikrishnan D., and Ebadi M. SKF-38393, a dopamine receptor agonist, attenuates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. Brain Research 892 2 (2001) 241-247
25. Muralikrishnan D., and Mohanakumar K.P. Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. FASEB Journal 12 10 (1998) 905-912
26. Muralikrishnan D., Ebadi M., and Brown-Borg H. Dopamine agonist 3-PPP fails to protect against MPTP-induced toxicity. Neurochemical Research 29 2 (2004) 379-384
27. Palkovits M., and Brownstein M.J. Brain Microdissection Techniques (1983), John Wiley and Sons, New York
28. Papucci L., Schiavone N., Witort E., Donnini M., Lapucci A., Tempestini A., Formigli Zecchi-Orlandini S., Orlandini G., Carella G., Brancato R., and Capaccioli S. Coenzyme q10 prevents apoptosis by inhibiting mitochondrial depolarization independently of its free radical scavenging property. The Journal of Biological Chemistry 278 30 (2003) 28220-28228
29. Przedborski S.V., Lewis J., and Fahn S. Antiparkinsonian therapies and brain mitochondrial complex I activity. Movement Disorder 10 3 (1995) 312-317
30. Rousseau G., and Varin F. Determination of ubiquinone-9 and 10 levels in rat tissues and blood by high performance liquid chromatography with ultraviolet detection. Journal of Chromatography 36 5 (1998) 247-252
31. Seyfried J., Soldner F., Kunz W.S., Schulz J.B., Klockgether T., Kovar K.A., and Wullner U. Effect of 1-methyl-4-phenylpyridinium on glutathione in rat pheochromocytoma PC-12cells. Neurochemistry International 36 6 (2000) 489-497
32. Shults C.W., and Haas R.H. Clinical trials of coenzyme Q10 in neurological disorders. BioFactors 25 1-4 (2005) 117-126
33. Shults C.W., Haas R.H., and Beal M.F. A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease. Biofactors 9 2-4 (1999) 267-272
34. Shults C.W., Oakes D., Kieburtz K., Beal M.F., Haas R., Plumb S., Juncos J.L., Nutt J., Shoulson I., Carter J., Kompoliti K., Perlmutter J.S., Reich S., Stern M., Watts R.L., Kurlan R., Molho E., Harrison M., Lew M., and Parkinson Study Group. . Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Archieves of Neurology 59 10 (2002) 1541-1550
35. Schulz J.B., Lindenau J., Seyfried J., and Dichgans J. Glutathione, oxidative stress and neurodegeneration. European Journal of Biochemistry 267 16 (2000) 4904-4911
36. Sohmiya M., Tanaka M., Tak N.W., Yanagisawa M., Tanino Y., Suzuki Y., Okamoto K., and Yamamoto Y. Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson's disease. Journal of the Neurological Sciences 223 2 (2004) 161-166
37. Sohmiya M., Tanaka M., Suzuki Y., Tanino Y., Okamoto K., and Yamamoto Y. An increase of oxidized coenzyme Q-10 occurs in the plasma of sporadic ALS patients. Journal of the Neurological Sciences 228 1 (2005) 49-53
38. Spina M.B., Squinto S.P., Miller J., Lindsay R.M., and Hyman C. Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system. Journal of Neurochemistry 59 1 (1992) 99-106
39. Sziraki I., Mohanakumar K.P., Rauhala P., Kim H.G., Yeh K.J., and Chiueh C.C. Manganese: a transition metal protects nigrostriatal neurons from oxidative stress in the iron-induced animal model of parkinsonism. Neuroscience 85 4 (1998) 1101-1111
40. Takahashi T., Okamoto T., Mori K., Sayo H., and Kishi T. Distribution of ubiquinone and ubiquinol homologues in rat tissues and subcellular fractions. Lipids 28 9 (1993) 803-809
41. Tanaka K., Fujita N., Yoshioka M., and Ogawa N. Immunosuppressive and non-immunosuppressive immunophilin ligands improve H(2)O(2)-induced cell damage by increasing glutathione levels in NG108-15 cells. Brain Research 889 1-2 (2001) 225-228
42. Thomas B., Muralikrishnan D., and Mohanakumar K.P. In vivo hydroxyl radical generation in the striatum following systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Brain Research 852 1 (2000) 221-224